原发睾丸弥漫大B细胞淋巴瘤临床特征、治疗及预后分析

目的:探讨原发睾丸弥漫大B细胞淋巴瘤（primary testicular diffuse large B-cell lymphoma,PT-DLBCL）的临床特征、治疗、疗效及预后。方法:收集宁夏医科大学总医院2012年04月至2022年04月收治的30例PT-DLBCL患者临床资料进行回顾性分析。结果:30例患者1、3、5年总生存率分别为93.1%、76.8%、66.3%；1、3、5年无进展生存率分别为79.7%、62.6%、62.6%。单因素分析显示:年龄、IPI评分、LDH水平、Hb水平、综合治疗模式、近期疗效与患者总生存均有关（P＜0.05）；年龄、IPI评分、Hb水平、综合治疗模式、是否联合利妥昔单抗、近期疗效与患者无进展生存均有关（P＜0.05）。多因素分析显示:是否联合利妥昔单抗是影响PT-DLBCL患者无进展生存的独立预后因素。结论:PT-DLBCL属罕见的侵袭性结外淋巴瘤，复发率较高，是否联合利妥昔单抗是影响PT-DLBCL患者无进展生存的独立预后因素。

Clinical characteristics,treatment and prognosis of primary testicular diffuse large B-cell lymphoma

Objective:To investigate the clinical features，treatment and prognosis of primary testicular diffuse large B-cell lymphoma（PT-DLBCL).Methods:The clinical data of 30 PT-DLBCL patients treated in General Hospital of Ningxia Medical University from April 2012 to April 2022 were retrospectively analyzed.Results:The 1,3,5-year overall survival rates were 93.1%，76.8% and 66.3%,the 1,3,5-year progression-free survival rates were 79.7%，62.6% and 62.6%.Univariate analysis showed that age，IPI score，LDH level，Hb level，comprehensive treatment，therapeutic effcet were prognostic factors for overall survival（P＜0.05).Age,IPI score,Hb level,the using of rituximab,comprehensive treatment and therapeutic effcet were prognostic factors for progression-free survival（P＜0.05).Multivariate analysis showed that the using of rituximab were independent prognostic factors for progression-free survival.Conclusion:PT-DLBCL is a rare and aggressive extranodal lymphoma with a high recurrence rate.The using of rituximab was independent prognostic factors for progression-free survival.